ROBOSENSE
23.12.2021 15:02:07 CET | Business Wire | Press release
RoboSense announced a strategic partnership with Horizon Robotics, a global pioneer in edge AI computing platforms. The two partners will mobilize their respective technological capacity and mass production experience to roll out in-depth cooperation focusing on advanced driver assistance systems (ADAS), autonomous driving, robotics, new intelligent transportation infrastructure and other applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211223005234/en/
Leveraging its leading smart LiDAR software and hardware technologies, RoboSense will join hands with Horizon Robotics to promote the large-scale commercialization of all segments of intelligent connected vehicle.
According to the partnership agreement, based on RoboSense’s second generation smart solid-state LiDAR RS-LiDAR-M1 (hereinafter referred to as "M1") and Horizon Robotics’ Journey 3 and Journey 5 automotive smart chips, the two companies will collaborate on the development and adaptation of integrated perception solutions for high-level autonomous driving pre-installed mass production. In the future, the partners will mobilize their respective advantageous industry resources to jointly promote the all-round standardized implementation of the domestic intelligent connected transportation industry.
Dr. Chunxin Qiu, founder and CEO of RoboSense:
" This strategic partnership will form a greater joint force and empower the two companies to create more visionary intelligent driving product solutions for the industry, to jointly build a prosperous ecology of the vehicle intelligence industry and advance the development of the intelligent connected transportation industry. "
Dr. Kai Yu, founder and CEO of Horizon Robotics:
" Through this strategic partnership, the two companies will fully complement each other with respective advantageous resources, jointly explore cutting-edge technologies and promote the mass production and large-scale implementation of pioneering intelligent driving solutions of the industry, leveraging technological innovation to build a safer and better smart mobility experience for the future. "
RoboSense is currently the only company in China to realize the automotive-grade domestic mass production of pre-installed LiDAR. Its second generation smart solid-state LiDAR, M1, has obtained pre-installed fixed-point project orders from multiple brands including GAC AION, WM Motor, ZEEKR, Lotus Cars, Inceptio and Zhito, covering models including passenger cars and commercial vehicles.
Horizon Robotics is a global leader in edge AI computing platforms based on the forward-looking concept of software and hardware integration As the only company in China to realize the automotive-grade domestic mass production of pre-installed AI chips, Horizon Robotics has reached intended partnership on priority mass production delivery with multiple car manufacturers including SAIC Motor, GWM, JAC Group, Changan Auto and BYD.
RoboSense and Horizon Robotics have a profound partnership history. The two companies announced intended partnership as early as 2019, and have been discussing and exploring innovations and integration solutions of vehicle intelligence technology, laying a solid foundation for the implementation of long-term and stable partnership achievements in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005234/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press release
Partnership Will Enable Enterprises to Accelerate AI Adoption While Ensuring Digital Sovereignty ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to oper
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom